Literature DB >> 28153651

Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.

Janki V Andhariya1, Stephanie Choi2, Yan Wang2, Yuan Zou2, Diane J Burgess1, Jie Shen3.   

Abstract

The objective of the present study was to develop a discriminatory and reproducible accelerated release testing method for naltrexone loaded parenteral polymeric microspheres. The commercially available naltrexone microsphere product (Vivitrol®) was used as the testing formulation in the in vitro release method development, and both sample-and-separate and USP apparatus 4 methods were investigated. Following an in vitro drug stability study, frequent media replacement and addition of anti-oxidant in the release medium were used to prevent degradation of naltrexone during release testing at "real-time" (37°C) and "accelerated" (45°C), respectively. The USP apparatus 4 method was more reproducible than the sample-and-separate method. In addition, the accelerated release profile obtained using USP apparatus 4 had a shortened release duration (within seven days), and good correlation with the "real-time" release profile. Lastly, the discriminatory ability of the developed accelerated release method was assessed using compositionally equivalent naltrexone microspheres with different release characteristics. The developed accelerated USP apparatus 4 release method was able to detect differences in the release characteristics of the prepared naltrexone microspheres. Moreover, a linear correlation was observed between the "real-time" and accelerated release profiles of all the formulations investigated, suggesting that the release mechanism(s) may be similar under both conditions. These results indicate that the developed accelerated USP apparatus 4 method has the potential to be an appropriate fast quality control tool for long-acting naltrexone PLGA microspheres.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Accelerated in vitro release testing; Compositionally equivalent; Naltrexone; PLGA microspheres; USP apparatus 4

Mesh:

Substances:

Year:  2017        PMID: 28153651     DOI: 10.1016/j.ijpharm.2017.01.050

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Drug release testing of long-acting intrauterine systems.

Authors:  Quanying Bao; Yuan Zou; Yan Wang; Darby Kozak; Stephanie Choi; Diane J Burgess
Journal:  J Control Release       Date:  2019-11-13       Impact factor: 9.776

2.  The Anti-Inflammation and Anti-Nociception Effect of Ketoprofen in Rats Could Be Strengthened Through Co-Delivery of a H2S Donor, S-Propargyl-Cysteine.

Authors:  Yue Yu; Qinyan Yang; Zhou Wang; Qian Ding; Meng Li; Yudong Fang; Qida He; Yi Zhun Zhu
Journal:  J Inflamm Res       Date:  2021-11-09

3.  Coupling the in vivo performance to the in vitro characterization of PLGA microparticles.

Authors:  Andrew Otte; Frederick Damen; Craig Goergen; Kinam Park
Journal:  Int J Pharm       Date:  2021-05-26       Impact factor: 6.510

4.  Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles.

Authors:  Farrokh Sharifi; Andrew Otte; Gwangheum Yoon; Kinam Park
Journal:  J Control Release       Date:  2020-07-07       Impact factor: 11.467

5.  Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol®.

Authors:  Yabing Hua; Zengming Wang; Dan Wang; Xiaoming Lin; Boshi Liu; Hui Zhang; Jing Gao; Aiping Zheng
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

6.  Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose.

Authors:  Farrokh Sharifi; Yazan J Meqbil; Andrew Otte; Anna M Gutridge; Arryn T Blaine; Richard M van Rijn; Kinam Park
Journal:  Pharm Res       Date:  2021-06-10       Impact factor: 4.580

Review 7.  Challenges and Complications of Poly(lactic-co-glycolic acid)-Based Long-Acting Drug Product Development.

Authors:  Yi Wen Lim; Wen Siang Tan; Kok Lian Ho; Abdul Razak Mariatulqabtiah; Noor Hayaty Abu Kasim; Noorsaadah Abd Rahman; Tin Wui Wong; Chin Fei Chee
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.